Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count. Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause. It may also be used to increase white blood cells for gathering during leukapheresis. It is given either by injection into a vein or under the skin. Filgrastim is a leukocyte growth factor.
Read the full article on WikipediaChemotherapy-induced neutropenia Clinical criteria: Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission, AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days.
Mobilisation of peripheral blood progenitor cells Clinical criteria: The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy.
Assisting bone marrow transplantation Clinical criteria: Patient must be receiving marrow-ablative chemotherapy prior to the transplantation.
Assisting autologous peripheral blood progenitor cell transplantation Clinical criteria: The treatment must be following marrow-ablative chemotherapy for non-myeloid malignancy prior to the transplantation.
Severe congenital neutropenia Clinical criteria: Patient must have an absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, AND Patient must have had a bone marrow examination that has shown evidence of maturational arrest of the neutrophil lineage.
Severe chronic neutropenia Clinical criteria: Patient must have an absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; OR Patient must have neutrophil dysfunction, AND Patient must have experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months; OR Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months.
Chronic cyclical neutropenia Clinical criteria: Patient must have an absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, AND Patient must have experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics; OR Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months.
“G-CSF is a colony stimulating factor which has been shown to have minimal direct in vivo or in vitro effects on the production of other haematopoietic cell types. Neupogen (filgrastim) is the name for recombinant methionyl human granulocyte colony stimulating factor (r-metHuG-CSF).”
Working under the parallel aged-care framework? Aged-care equivalent →